Samsung BioLogics Co's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2025 was ₩5,277.00.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was ₩17,978.00.
Samsung BioLogics Co's EPS without NRI for the
three
months ended in Mar. 2025 was ₩5,287.35.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was 18,551.88.
During the past 12 months, Samsung BioLogics Co's average EPS without NRIGrowth Rate was 47.30% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 38.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 42.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 11 years, Samsung BioLogics Co's highest 3-Year average EPS without NRI Growth Rate was 51.80% per year. The lowest was -63.00% per year. And the median was 43.65% per year.
Samsung BioLogics Co EPS (Basic) Historical Data
The historical data trend for Samsung BioLogics Co's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Samsung BioLogics Co's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩17,978.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samsung BioLogics Co (XKRX:207940) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Samsung BioLogics Co EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Samsung BioLogics Co's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:207940 has been successfully added to your 